Table 3 Procedural details

Indications for surgery (# per patient, Mean ± SD)

2.4 ± 0.9

2.3 ± 0.9

2.4 ± 1.0

 Degenerative disc disease (DDD)

60 (63.2%)

34 (70.8%)

26 (55.3%)

 Herniated nucleus pulposus (HNP)

14 (14.7%)

7 (14.6%)

7 (14.9%)

 Spondylosis

49 (51.6%)

22 (45.8%)

27 (57.4%)

 Spondylolisthesis

25 (26.3%)

1 (2.1%)

24 (51.1%)

 Stenosis

66 (69.5%)

45 (93.8%)

21 (44.7%)

 Other

9 (9.5%)

2 (4.2%)

7 (14.9%)

Surgery type

 ACDF

48 (50.5%)

48 (100.0%)

–

  MIS

–

30 (62.5%)

–

  Open

–

18 (37.5%)

–

 ALIF

25 (26.3%)

–

25 (53.2%)

  MIS

–

–

25 (100.0%)

 TLIF

21 (22.1%)

–

21 (44.7%)

  MIS

–

–

3 (14.3%)

  Open

–

–

18 (85.7%)

 PLIF

1 (1.1%)

–

1 (2.1%)

  Open

–

–

1 (100.0%)

Levels treated

n = 160

n = 93

n = 67

 # Levels Treated (1–3), (Mean ± SD)

1.7 ± 0.6

1.9 ± 0.6

1.4 ± 0.6

 C3–C4

4 (2.5%)

4 (4.3%)

–

 C4–C5

17 (10.6%)

17 (18.3%)

–

 C5–C6

39 (24.4%)

39 (41.9%)

–

 C6–C7

33 (20.6%)

33 (35.5%)

–

 L2–L3

1 (0.6%)

–

1 (1.5%)

 L3–L4

8 (5.0%)

–

8 (11.9%)

 L4–L5

29 (18.1%)

–

29 (43.3%)

 L5–S1

29 (18.1%)

–

29 (43.3%)

Revision of a previous surgery?

7 (7.4%)

2 (4.2%)

5 (10.6%)

Interbody implant used during procedure

PEEK—Titanium Coating

34 (35.8%)

22 (45.8%)

12 (25.5%)

PEEK—Traditional

7 (7.4%)

0 (0.0%)

7 (14.9%)

Vertu stand-alone with Ti-Bond

21 (22.1%)

20 (41.7%)

1 (2.1%)

Titanium mesh cage

14 (14.7%)

0 (0.0%)

14 (29.8%)

Spinal elements magnum + with Ti-bond

11 (11.6%)

2 (4.2%)

9 (19.1%)

Spinal elements magnum + with mercury

2 (2.1%)

0 (0.0%)

2 (4.3%)

PEKK—Tetrafuse

2 (2.1%)

2 (4.2%)

0 (0.0%)

Other

4 (4.2%)

2 (4.2%)

2 (4.3%)

Total amount of ViBone used across all levels

cc, (Mean ± SD)

 Volume used for 1 level

6.1 ± 3.0

2.8 ± 1.6

7.2 ± 2.6

 Volume used for 2 levels

5.9 ± 3.0

4.0 ± 1.5

9.5 ± 1.4

 Volume used for 3 levels

7.0 ± 4.6

4.7 ± 0.8

15.0 ± 0.0